

HealthCare Global Enterprises Ltd. reports Q3 FY17 results

Revenue growth of 23% (y-o-y)

EBITDA growth of 25% (y-o-y)

PAT of INR 54 mn

Bengaluru, February 08, 2017: Healthcare Global Enterprises Limited (“HCG”) today announced its financial results for the quarter ended December 31, 2016 (“Q3 FY17”).

Highlights for the quarter ended December 31, 2016 (Q3 FY17)

- Consolidated Income from Operations (“Revenue”) was **INR 1,762 mn** as compared to **INR 1,435 mn** in the corresponding quarter of the previous year, reflecting a year-on-year increase of **22.8%**.
- Consolidated Profit Before Other Income, Depreciation and Amortization, Finance Costs, Exceptional Items and Taxes (“EBITDA”) was **INR 260 mn** as compared to **INR 208 mn** in the corresponding quarter of the previous year, reflecting a year-on-year increase of **25.2%**.
- Consolidated Profit before Taxes and Exceptional items (“PBT”) was **INR 77 million** as compared to **INR 15 mn** in the corresponding quarter of the previous year, reflecting a year-on-year increase of **402%**.
- Consolidated Profit after Taxes and Minority Interest (“PAT”) was **INR 54 million** as compared to a **loss of INR 22 mn** in the corresponding quarter of the previous year.
- EBITDA excluding losses from new centers was **INR 274 mn**, reflecting a margin of **17.3%** and a growth of **25.6%** over the corresponding quarter of the previous year.

INR million except earnings per share

Period Ended Dec 31	Q3-FY17	Q3-FY16	Growth (y-o-y)	YTD-FY17	YTD-FY16	Growth (y-o-y)
Income from Operations	1,761.5	1,434.5	22.8%	5,176.8	4,291.3	20.6%
EBITDA⁽¹⁾	260.0	207.7	25.2%	750.3	598.2	25.4%
<i>EBITDA Margin (%)</i>	<i>14.8%</i>	<i>14.5%</i>		<i>14.5%</i>	<i>13.9%</i>	
PBT⁽²⁾	76.8	15.3	402.0%	231.7	34.8	565.8%
<i>PBT Margin (%)</i>	<i>4.4%</i>	<i>1.1%</i>		<i>4.5%</i>	<i>0.8%</i>	
PAT⁽³⁾	53.5	(21.9)	NM	152.7	(43.2)	NM
<i>PAT Margin (%)</i>	<i>3.0%</i>	<i>-1.5%</i>		<i>2.9%</i>	<i>-1.0%</i>	
Earnings Per Share	0.62	(0.30)	NM	1.79	(0.60)	NM

(1) Profit before other income, depreciation and amortization, finance costs, exceptional items and taxes

(2) Profit / (Loss) before tax and exceptional items

(3) Profit / (Loss) for the period after taxes and minority interests

Business Updates for Q3 FY17

- New cancer centers at Kalaburagi, Vadodara and Visakhapatnam continued to ramp satisfactorily resulting in the overall losses from new centers reducing in the quarter
- Strong growth in Gujarat continues further strengthening HCG presence and market share in the region
- Milann was ranked No. 1 nationally for the second consecutive year in the “All India Fertility & IVF Ranking Survey 2017” of the Times of India. A new Milann center in Chandigarh was launched strengthening our North India presence.

Commenting on the results, **Dr. B.S. Ajaikumar, Chairman, HealthCare Global Enterprises Ltd.** said, “We are pleased to report continued strong results for the third quarter of FY 2017, despite the moderate impacts of demonetization in certain sectors. Notwithstanding, we do not expect any material impact in the longer term and given our expanding national footprint and specialist focus, we remain very excited about the growth opportunities ahead of us. By making the highest quality of cancer care accessible to patients across India, we continue to create meaningful social impact, whilst delivering efficient returns to stakeholders. ”

Q3 FY17 Earnings Call

The company will conduct a one hour conference call at **5:00 PM IST on Wednesday, February 08, 2017** where the management will discuss insights about the company’s performance and answer questions from participants. To participate in this conference call, please dial the numbers provided below ten minutes ahead of the scheduled start time. The dial-in number for this call is **+91 22 3960 0644 / +91 22 3940 3977**. Other numbers are listed in the conference call invite which is uploaded on the stock exchange and posted on our website.

About HCG Enterprises Ltd.:

HealthCare Global Enterprises Ltd. (HCG), headquartered in Bengaluru, is the largest provider of cancer care in India. Through its network of 17 comprehensive cancer centers across India, HCG has brought advanced cancer care to the doorstep of millions of people. HCG’s comprehensive cancer centers provide expertise and advanced technologies required for the effective diagnosis and treatment of cancer under one roof. HCG has pioneered the introduction and adoption of several technologies in the country including stereotactic radiosurgery, robotic radiosurgery and the use of genomics for personalized treatment of cancer. Under the “Milann” brand, HCG operates 7 fertility centers. **For further information, visit www.hcgel.com or contact: Company Secretary and Compliance Officer: Sunu Manuel, investors@hcgoncology.com**